Literature DB >> 33472354

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia.

Andreas Burchert1.   

Abstract

FLT3-ITD is a constitutively activated variant of the FLT3 tyrosine kinase receptor. Its expression in acute myeloid leukemia (AML) is associated with a poor prognosis. Due to this, the development of tyrosine kinase inhibitors (TKI) blocking FLT3-ITD became a rational therapeutic concept. This review describes key milestones in the clinical development of different FLT3-specific TKI with a particular focus on FLT3-TKI maintenance therapy in remission after allogeneic hematopoietic stem cell transplantation (HCT). Recent evidence from randomized trials using sorafenib in FLT3-ITD mutated AML provided a proof of concept that targeted post-HCT maintenance therapy could become a new treatment paradigm in AML.

Entities:  

Year:  2021        PMID： 33472354      PMCID： PMC7927878          DOI： 10.3324/haematol.2019.240747

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  66 in total

1.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

2.  Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Authors:  Richard F Schlenk; Daniela Weber; Walter Fiedler; Helmut R Salih; Gerald Wulf; Hans Salwender; Thomas Schroeder; Thomas Kindler; Michael Lübbert; Dominik Wolf; Jörg Westermann; Doris Kraemer; Katharina S Götze; Heinz-August Horst; Jürgen Krauter; Michael Girschikofsky; Mark Ringhoffer; Thomas Südhoff; Gerhard Held; Hans-Günter Derigs; Roland Schroers; Richard Greil; Martin Grießhammer; Elisabeth Lange; Alexander Burchardt; Uwe Martens; Bernd Hertenstein; Lore Marretta; Michael Heuser; Felicitas Thol; Verena I Gaidzik; Wolfgang Herr; Julia Krzykalla; Axel Benner; Konstanze Döhner; Arnold Ganser; Peter Paschka; Hartmut Döhner
Journal:  Blood       Date:  2018-12-18       Impact factor: 22.113

3.  Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.

Authors:  H Kiyoi; M Towatari; S Yokota; M Hamaguchi; R Ohno; H Saito; T Naoe
Journal:  Leukemia       Date:  1998-09       Impact factor: 11.528

4.  A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Authors:  Steven Knapper; Alan K Burnett; Tim Littlewood; W Jonathan Kell; Sam Agrawal; Raj Chopra; Richard Clark; Mark J Levis; Donald Small
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

Review 5.  FLT3 as a therapeutic target in AML: still challenging after all these years.

Authors:  Thomas Kindler; Daniel B Lipka; Thomas Fischer
Journal:  Blood       Date:  2010-08-12       Impact factor: 22.113

6.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Authors:  Keith W Pratz; Takashi Sato; Kathleen M Murphy; Adam Stine; Trivikram Rajkhowa; Mark Levis
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

7.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Authors:  B Douglas Smith; Mark Levis; Miloslav Beran; Francis Giles; Hagop Kantarjian; Karin Berg; Kathleen M Murphy; Tianna Dauses; Jeffrey Allebach; Donald Small
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

8.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

9.  DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.

Authors:  Timothy J Ley; Elaine R Mardis; Li Ding; Bob Fulton; Michael D McLellan; Ken Chen; David Dooling; Brian H Dunford-Shore; Sean McGrath; Matthew Hickenbotham; Lisa Cook; Rachel Abbott; David E Larson; Dan C Koboldt; Craig Pohl; Scott Smith; Amy Hawkins; Scott Abbott; Devin Locke; Ladeana W Hillier; Tracie Miner; Lucinda Fulton; Vincent Magrini; Todd Wylie; Jarret Glasscock; Joshua Conyers; Nathan Sander; Xiaoqi Shi; John R Osborne; Patrick Minx; David Gordon; Asif Chinwalla; Yu Zhao; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark Watson; Jack Baty; Jennifer Ivanovich; Sharon Heath; William D Shannon; Rakesh Nagarajan; Matthew J Walter; Daniel C Link; Timothy A Graubert; John F DiPersio; Richard K Wilson
Journal:  Nature       Date:  2008-11-06       Impact factor: 49.962

10.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Authors:  Alexander E Perl; Giovanni Martinelli; Jorge E Cortes; Andreas Neubauer; Ellin Berman; Stefania Paolini; Pau Montesinos; Maria R Baer; Richard A Larson; Celalettin Ustun; Francesco Fabbiano; Harry P Erba; Antonio Di Stasi; Robert Stuart; Rebecca Olin; Margaret Kasner; Fabio Ciceri; Wen-Chien Chou; Nikolai Podoltsev; Christian Recher; Hisayuki Yokoyama; Naoko Hosono; Sung-Soo Yoon; Je-Hwan Lee; Timothy Pardee; Amir T Fathi; Chaofeng Liu; Nahla Hasabou; Xuan Liu; Erkut Bahceci; Mark J Levis
Journal:  N Engl J Med       Date:  2019-10-31       Impact factor: 91.245
View more
  6 in total

Review 1.  Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.

Authors:  Garrett M Dancik; Ioannis F Voutsas; Spiros Vlahopoulos
Journal:  Mol Biol Rep       Date:  2022-01-14       Impact factor: 2.316

2.  Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Zixuan Zhang; Yuta Hasegawa; Daigo Hashimoto; Hajime Senjo; Ryo Kikuchi; Xuanzhong Chen; Kazuki Yoneda; Tomoko Sekiguchi; Tatsuya Kawase; Hirofumi Tsuzuki; Takashi Ishio; Takahide Ara; Hiroyuki Ohigashi; Masao Nakagawa; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2022-02-28       Impact factor: 5.483

Review 3.  Which FLT3 Inhibitor for Treatment of AML?

Authors:  Jayastu Senapati; Tapan Mahendra Kadia
Journal:  Curr Treat Options Oncol       Date:  2022-03-08

4.  Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment.

Authors:  Lili Li; Wenliang Wang; Li Liang; Jian Ge; Ruixiang Xia
Journal:  Dis Markers       Date:  2022-07-05       Impact factor: 3.464

5.  Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert Gerbing; Patrick Brown; Elizabeth Fox; John Choi; Brian Fisher; Betsy Hirsch; Samir Kahwash; Kelly Getz; John Levine; Lisa Eidenschink Brodersen; Michael R Loken; Susana Raimondi; Katherine Tarlock; Andrew Wood; Lillian Sung; E Anders Kolb; Alan Gamis; Soheil Meshinchi; Richard Aplenc
Journal:  J Clin Oncol       Date:  2022-03-29       Impact factor: 50.717

Review 6.  Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.

Authors:  Salvatore Leotta; Annalisa Condorelli; Roberta Sciortino; Giulio Antonio Milone; Claudia Bellofiore; Bruno Garibaldi; Giovanni Schininà; Andrea Spadaro; Alessandra Cupri; Giuseppe Milone
Journal:  J Clin Med       Date:  2022-01-04       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.